- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00061958
Arsenic Trioxide in Treating Patients With Advanced Cancer of the Esophagus or Gastroesophageal Junction
A Phase II Study of Arsenic Trioxide (NSC 706363) in Patients With Advanced Adenocarcinoma of the Esophagus or Gastroesophageal Junction
Study Overview
Status
Intervention / Treatment
Detailed Description
OBJECTIVES:
I. Determine the response rate and duration of response in patients with advanced adenocarcinoma of the esophagus or gastroesophageal junction treated with arsenic trioxide.
II. Determine the toxicity of this drug in these patients.
OUTLINE: This is an open-label study.
Patients receive a loading dose of arsenic trioxide IV over 2 hours on days 1-5 on week 1. Beginning on week 2, patients receive a maintenance dose of arsenic trioxide IV twice weekly thereafter. Courses repeat every 4 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) continue to receive therapy for at least 6 months beyond CR.
Patients are followed every 3 months for 6 months or until disease progression.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- M D Anderson Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Histologically confirmed adenocarcinoma of the esophagus or gastroesophageal junction
- Metastatic or unresectable local-regional disease
- Osseous metastasis as the only site of disease not eligible
Measurable disease
- Mediastinal or hilar lymph nodes must be at least 2.0 cm in diameter by CT scan or MRI to be considered measurable
- No known brain metastases
- Performance status - Zubrod 0-2
- Performance status - Karnofsky 60-100%
- At least 12 weeks
- Absolute granulocyte count at least 1,500/mm^3
- Platelet count at least 100,000/mm^3
- Hemoglobin at least 8 g/dL
- Bilirubin no greater than 1.5 mg/dL
- SGOT and/or SGPT no greater than 2.0 times upper limit of normal (ULN)
- Creatinine no greater than 1.5 times ULN
- Creatinine clearance at least 60 mL/min
- Calcium no greater than 12 mg/dL
- No symptomatic hypercalcemia under treatment
- No New York Heart Association class III or IV heart disease
- No angina within the past 6 months
- No myocardial infarction within the past 6 months
- No congestive heart failure within the past 6 months
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
No other concurrent active malignancy except nonmelanoma skin cancer or carcinoma in situ of the cervix
- Prior malignancies with no evidence of disease for at least 2 years are allowed
- No serious concurrent infection that is uncontrolled or whose control could be jeopardized by complications of study therapy
- No concurrent nonmalignant medical illness that is uncontrolled or whose control could be jeopardized by complications of study therapy
- No psychiatric disorder or other condition that would preclude study compliance
- No prior immunotherapy (including adjuvant or preoperative regimens)
- No concurrent biological response modifiers
- No concurrent filgrastim (G-CSF) or sargramostim (GM-CSF)
- No prior chemotherapy (including adjuvant or preoperative regimens and radiosensitizers)
- At least 4 weeks since prior radiotherapy and recovered
- No prior radiotherapy to major bone marrow containing areas (e.g., pelvis or lumbar spine) or area that contained the indicator lesion
- No prior radiotherapy involving 30% or more of the bone marrow
- No concurrent radiotherapy
- At least 2 weeks since prior major surgery (4 days for minor surgery) and recovered
- No other concurrent investigational drugs
- No other concurrent antineoplastic therapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (arsenic trioxide)
Patients receive a loading dose of arsenic trioxide IV over 2 hours on days 1-5 on week 1.
Beginning on week 2, patients receive a maintenance dose of arsenic trioxide IV twice weekly thereafter.
Courses repeat every 4 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity.
Patients achieving a CR continue to receive therapy for at least 6 months beyond CR.
|
Given IV
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Objective response (OR) defined as a complete or partial remission, evaluated using RECIST criteria
Time Frame: 8 weeks
|
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Duration of response
Time Frame: From the time measurement criteria are met for CR or PR until the first date that recurrent or progressive disease is objectively documented, assessed up to 6 months
|
From the time measurement criteria are met for CR or PR until the first date that recurrent or progressive disease is objectively documented, assessed up to 6 months
|
Toxicity graded according to the Common Toxicity Criteria version 2
Time Frame: Up to 6 months
|
Up to 6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jaffer Ajani, M.D. Anderson Cancer Center
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Head and Neck Neoplasms
- Esophageal Diseases
- Adenocarcinoma
- Esophageal Neoplasms
- Antineoplastic Agents
- Arsenic Trioxide
Other Study ID Numbers
- NCI-2012-02534
- N01CM17003 (U.S. NIH Grant/Contract)
- DM02-172
- CDR0000302483 (Registry Identifier: PDQ (Physician Data Query))
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Adenocarcinoma of the Esophagus
-
Jules Bordet InstituteInnate PharmaWithdrawnAdenocarcinoma of the Gastroesophageal Junction | Squamous Cell Carcinoma of the Esophagus | Adenocarcinoma of the EsophagusBelgium
-
Accelerated Community Oncology Research NetworkAmgenTerminatedGastroesophageal Adenocarcinoma | Adenocarcinomas of the Gastroesophageal Junction | Adenocarcinoma of the Distal Esophagus | Adenocarcinoma of the Proximal StomachUnited States
-
Translational Oncology Research InternationalSanofi; University of California, Los Angeles; OSI PharmaceuticalsCompletedUnresectable Adenocarcinoma of the Esophagus | Metastatic Adenocarcinoma of the Esophagus | Unresectable Adenocarcinoma of Gastric Cardia | Metastatic Adenocarcinoma of Gastric CardiaUnited States
-
Case Comprehensive Cancer CenterTerminatedAdenocarcinoma of the Gastroesophageal Junction | Adenocarcinoma of the EsophagusUnited States
-
University of BolognaCompletedAdenocarcinoma of the Esophagus | Adenocarcinoma of the Gastric CardiaItaly
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedAdenocarcinoma of the Gastroesophageal Junction | Stage II Gastric Cancer | Stage III Gastric Cancer | Squamous Cell Carcinoma of the Esophagus | Adenocarcinoma of the Stomach | Adenocarcinoma of the Esophagus | Stage III Esophageal Cancer | Stage II Esophageal CancerUnited States
-
Erasmus Medical CenterNot yet recruitingEsophageal Cancer | Adenocarcinoma of the Esophagus
-
Lund University HospitalCompletedAdenocarcinoma of the Esophagus or Esophagogastric JunctionSweden
-
Burzynski Research InstituteTerminatedAdenocarcinoma of the EsophagusUnited States
-
University of Colorado, DenverNational Cancer Institute (NCI)RecruitingAdenocarcinoma of the Gastroesophageal Junction | Adenocarcinoma EsophagusUnited States
Clinical Trials on arsenic trioxide
-
Ruijin HospitalRecruitingRefractory Solid TumorsChina
-
CTI BioPharmaTerminatedMultiple Myeloma and Plasma Cell NeoplasmUnited States
-
Albert Einstein College of MedicineNational Cancer Institute (NCI)CompletedProstate CancerUnited States
-
National Cancer Institute (NCI)CompletedLymphoma | LeukemiaUnited States, Canada, Australia
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)CompletedLymphoma | Leukemia | Multiple Myeloma and Plasma Cell NeoplasmUnited States
-
Southwest Oncology GroupNational Cancer Institute (NCI)CompletedTesticular Germ Cell Tumor | Extragonadal Germ Cell TumorUnited States
-
Washington University School of MedicineNational Cancer Institute (NCI)Completed
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Withdrawn
-
Northwestern UniversityNational Cancer Institute (NCI)TerminatedLymphomaUnited States
-
Northwestern UniversityNational Cancer Institute (NCI)Completed